154 related articles for article (PubMed ID: 35363385)
1. Anticancer effects of disulfiram in T-cell malignancies through NPL4-mediated ubiquitin-proteasome pathway.
Chen C; Nie D; Huang Y; Yu X; Chen Z; Zhong M; Liu X; Wang X; Sui S; Liu Z; Tan J; Yu Z; Li Y; Zeng C
J Leukoc Biol; 2022 Oct; 112(4):919-929. PubMed ID: 35363385
[TBL] [Abstract][Full Text] [Related]
2. Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma.
Yoshino H; Yamada Y; Enokida H; Osako Y; Tsuruda M; Kuroshima K; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M
PLoS One; 2020; 15(7):e0236119. PubMed ID: 32667929
[TBL] [Abstract][Full Text] [Related]
3. Disulfiram promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells.
Li L; Yang H; Chen D; Cui C; Dou QP
Toxicol Appl Pharmacol; 2008 Jun; 229(2):206-14. PubMed ID: 18304598
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
5. Identification of novel dithiocarbamate-copper complexes targeting p97/NPL4 pathway in cancer cells.
Loffelmann M; Škrott Z; Majera D; Štarha P; Kryštof V; Mistrík M
Eur J Med Chem; 2023 Dec; 261():115790. PubMed ID: 37690264
[TBL] [Abstract][Full Text] [Related]
6. The disulfiram/copper complex induces apoptosis and inhibits tumour growth in human osteosarcoma by activating the ROS/JNK signalling pathway.
Guo W; Zhang X; Lin L; Wang H; He E; Wang G; Zhao Q
J Biochem; 2021 Oct; 170(2):275-287. PubMed ID: 33792698
[TBL] [Abstract][Full Text] [Related]
7. Disulfiram, and disulfiram derivatives as novel potential anticancer drugs targeting the ubiquitin-proteasome system in both preclinical and clinical studies.
Kona FR; Buac D; M Burger A
Curr Cancer Drug Targets; 2011 Mar; 11(3):338-46. PubMed ID: 21247383
[TBL] [Abstract][Full Text] [Related]
8. The value of proteasome inhibition in cancer. Can the old drug, disulfiram, have a bright new future as a novel proteasome inhibitor?
Cvek B; Dvorak Z
Drug Discov Today; 2008 Aug; 13(15-16):716-22. PubMed ID: 18579431
[TBL] [Abstract][Full Text] [Related]
9. An Updated Review of Disulfiram: Molecular Targets and Strategies for Cancer Treatment.
Yang Q; Yao Y; Li K; Jiao L; Zhu J; Ni C; Li M; Dou QP; Yang H
Curr Pharm Des; 2019; 25(30):3248-3256. PubMed ID: 31419930
[TBL] [Abstract][Full Text] [Related]
10. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
Chen D; Cui QC; Yang H; Dou QP
Cancer Res; 2006 Nov; 66(21):10425-33. PubMed ID: 17079463
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram/Copper Induces Immunogenic Cell Death and Enhances CD47 Blockade in Hepatocellular Carcinoma.
Gao X; Huang H; Pan C; Mei Z; Yin S; Zhou L; Zheng S
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230638
[TBL] [Abstract][Full Text] [Related]
12. Two clinical drugs deubiquitinase inhibitor auranofin and aldehyde dehydrogenase inhibitor disulfiram trigger synergistic anti-tumor effects in vitro and in vivo.
Huang H; Liao Y; Liu N; Hua X; Cai J; Yang C; Long H; Zhao C; Chen X; Lan X; Zang D; Wu J; Li X; Shi X; Wang X; Liu J
Oncotarget; 2016 Jan; 7(3):2796-808. PubMed ID: 26625200
[TBL] [Abstract][Full Text] [Related]
13. Overcoming the compensatory increase in NRF2 induced by NPL4 inhibition enhances disulfiram/copper-induced oxidative stress and ferroptosis in renal cell carcinoma.
Ni X; Ye C; Yu X; Zhang Y; Hou Y; Zheng Q; Chen Z; Wang L; Weng X; Yang C; Liu X
Eur J Pharmacol; 2023 Dec; 960():176110. PubMed ID: 37838104
[TBL] [Abstract][Full Text] [Related]
14. Targeting the NPL4 Adaptor of p97/VCP Segregase by Disulfiram as an Emerging Cancer Vulnerability Evokes Replication Stress and DNA Damage while Silencing the ATR Pathway.
Majera D; Skrott Z; Chroma K; Merchut-Maya JM; Mistrik M; Bartek J
Cells; 2020 Feb; 9(2):. PubMed ID: 32085572
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram/Copper induces antitumor activity against gastric cancer via the ROS/MAPK and NPL4 pathways.
Liu Y; Guan X; Wang M; Wang N; Chen Y; Li B; Xu Z; Fu F; Zheng Z; Du C
Bioengineered; 2022 Mar; 13(3):6579-6589. PubMed ID: 35290151
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.
Conticello C; Martinetti D; Adamo L; Buccheri S; Giuffrida R; Parrinello N; Lombardo L; Anastasi G; Amato G; Cavalli M; Chiarenza A; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F
Int J Cancer; 2012 Nov; 131(9):2197-203. PubMed ID: 22322883
[TBL] [Abstract][Full Text] [Related]
18. Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines.
Jivan R; Damelin LH; Birkhead M; Rousseau AL; Veale RB; Mavri-Damelin D
J Cell Biochem; 2015 Oct; 116(10):2334-43. PubMed ID: 25846272
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Repurposing Disulfiram and Disulfiram Derivatives as Copper-Dependent Anticancer Agents.
Kannappan V; Ali M; Small B; Rajendran G; Elzhenni S; Taj H; Wang W; Dou QP
Front Mol Biosci; 2021; 8():741316. PubMed ID: 34604310
[TBL] [Abstract][Full Text] [Related]
20. Disulfiram and copper combination therapy targets NPL4, cancer stem cells and extends survival in a medulloblastoma model.
Serra R; Zhao T; Huq S; Gorelick NL; Casaos J; Cecia A; Mangraviti A; Eberhart C; Bai R; Olivi A; Brem H; Jackson EM; Tyler B
PLoS One; 2021; 16(11):e0251957. PubMed ID: 34731160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
